Skip to content
Open access

A pan-cohort transcriptional landscape of breast cancer maps subtype and microenvironmental programs

Sep 2026 · bioRxiv · 0 citations
Biology

TL;DR

A unified, multi-cohort transcriptional landscape of breast cancer that organizes canonical subtypes along continuous biological axes and reveals spatially structured regions of therapeutic sensitivity and resistance is presented.

Abstract

Breast cancer comprises heterogeneous transcriptional states that are incompletely captured by discrete clinical or molecular subtype labels. To visualize this heterogeneity in a unified framework, we integrated bulk RNA-seq data from 2,284 patient samples across 13 studies using 18,089 protein coding genes, a harmonized processing pipeline, batch correction, consensus clustering and PaCMAP dimensionality reduction to construct an interactive breast cancer transcriptional landscape. Consensus clustering identified five major regions, which were annotated using PAM50 scores calculated for each sample: Luminal A, Luminal B, HER2-enriched, and two basal-associated clusters. The basal clusters separated into an immune-rich region marked by T cell–inflamed, tumor-associated macrophages (TAM), and low-purity signatures, and a cell-cycle–driven region enriched for proliferation and DNA replication programs. Overlay of marker genes, pathways, kinases, neuronal-like signaling programs, cancer associated fibroblasts (CAF) states, and TAM programs revealed spatially organized subtype biology and microenvironmental heterogeneity. Finally, projection of therapy-associated resistance signatures identified landscape regions linked to predicted resistance to HER2-targeted therapy and hormone receptor–directed endocrine therapies. By enabling interactive exploration of transcriptional states, marker genes, pathways, and therapeutic response programs, this resource provides a community framework for biomarker discovery in breast cancer. Significance statement We present a unified, multi-cohort transcriptional landscape of breast cancer that organizes canonical subtypes along continuous biological axes and reveals spatially structured regions of therapeutic sensitivity and resistance. By enabling projection of patient samples and patient-derived models into this framework, we provide a practical tool for interpreting tumor biology and guiding translational discovery. Graphical abstract caption We integrate 13 breast cancer transcriptomic datasets using a harmonized processing pipeline with batch correction and dimensionality reduction to construct a unified landscape spanning basal, HER2-enriched, luminal A, luminal B, and normal-like subtypes. Continuous gradients of proliferation, endocrine signaling, metabolic activity, and tissue architecture organize the space and recapitulate subtype biology. Overlay of clinical outcomes reveals high-risk regions beyond discrete subtype boundaries, while integration of gene expression and copy number alterations links genomic events to pathway-level programs. Microenvironmental features, including cancer-associated fibroblast programs, map to distinct regions of the landscape. Projection of drug response signatures identifies zones of sensitivity and intrinsic resistance. The framework supports embedding of patient samples and patient-derived xenograft models and is available as an interactive resource for exploration and projection of new datasets. One Sentence Summary A landscape built using only transcriptomic analysis for breast cancer reveals novel insights about subtype-specific biology.

Read PDF

Similar papers

Open access Aug 2026

Single-cell profiling identifies STAT3/NF-κB regulatory hubs and cytokine crosstalk in the tumor microenvironment

Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.

M. O. Odubote, Chiemeka Elochi Emeribe · 0 citations
Sep 2026

Abstract PR007: Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations

Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive cellular and molecular heterogeneity. How unique malignant states interact with and organize local microenvironments to drive therapy resistance and progression remains poorly understood, limiting tumour profiling and patient stratification. Existing binary t...

Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al. · 0 citations
Open access Sep 2026

Multimodal integration of pathomics and single-cell transcriptomics reveals CDC20 as a link between prostate cancer recurrence and benzo[a]pyrene-responsive phenotypes

Introduction Prostate cancer recurrence reflects molecular and histological heterogeneity, yet the cellular states harboring recurrence-associated signals and their potential environmental modifiers remain incompletely understood. Methods We integrated single-cell RNA sequencing, bulk transcriptomes with recurrence ann...

Xu-Chao Dai, Wei Gu, Bo Yu et al. · 0 citations
Open access Aug 2026

Single-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations

Findings support rational drug combinations targeting HIF-1 together with upstream PI3K/AKT/mTOR, MAPK, MAPK, or JAK/STAT signaling in single-cell breast cancer atlases.

B. R. Yavuz, H. Jang, R. Nussinov · 0 citations
Open access Aug 2026

Multi-level Transcriptomic and Machine-learning Analyses Identify MZT1 as a Proliferation-associated Prognostic Marker in Lung Adenocarcinoma

MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.

Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.